1Pringsheim, T, Gardner, D. Dispensed prescriptions for quetiapine and other second generation antipsychotics in Canada from 2005 to 2012: a descriptive study. CMAJ Open 2014; 2(4): E225–32.
2Pringsheim, T, Lam, D, Patten, SB. The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents, 2005-2009. J Child Adolesc Psychopharmacol 2011; 21(6): 1–8.
3Divac, N, Prostran, M, Jakovcevski, I, Cerovac, N. Second generation antipsychotics and extrapyramidal adverse events. Biomed Res Int 2014; 2014: 656370.
4Chaplain, S, Taylor, M. Drug points: second generation antipsychotics. Prescriber 2014; 14(21): 12–21.
5McEvoy, J, Meyer, J, Goff, D, Nasrallah, HA, Davis, S, Sullivan, L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80(1): 19–32.
6Kurzthaler, I, Fleischhacker, WW. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 2001; 62(suppl 7): 32–7.
7Hagg, S, Lindblom, Y, Mjorndal, T, Adolfsoon, R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006; 21: 93–8.
8Brown, S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997; 171: 502–8.
9Mortensen, P, Juel, K. Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 1993; 163: 183–9.
10Harris, E, Barraclough, B. Excess mortality of mental disorder. Br J Psychiatry 1998; 173: 11–53.
11Laursen, T, Munk-Olsen, T, Vestergaard, M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry 2012; 25(2): 83–8.
13Tremblay, M, Wolfson, M, Gorber, S. Canadian Health Measures Survey: rationale, background and overview. Health Rep 2007; 18(suppl): 6–20.
14Bryan, S, St-Denis, M, Wojtas, D. Canadian Health Measures Survey: clinic operations and logistics. Health Rep 2007; 82(suppl): 52–70.
15NCEP–ATP III. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. (Adult Treatment Panel III). Final Report. Circulation 2002; 106: 3143–421.
16Alberti, K, Zimmet, P, Shaw, J. Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 2006; 23: 469–80.
17Alessi-Severini, S, Biscontri, R, Collins, D, Kozyrskyj, A, Sareen, J, Enns, M. Utilization and costs of antipsychotic agents: a Canadian population based study 1996-2006. Psychiatr Serv 2008; 59(5): 547–53.
18Alessi-Severini, S, Biscontri, R, Collins, D, Sareen, J, Enns, M. Ten years of antipsychotic prescribing to children: a Canadian population-based study. Can J Psychiatry 2012; 57(1): 52–8.
19Dewa, C, Remington, G, Herrmann, N, Fearnley, J, Goering, P. How much are atypical antipsychoitc agents being used, and do they reach the populations who need them? A Canadian experience. Clin Ther 2002; 24(9): 1466–76.
20Murphy, A, Gardner, DM, Cooke, C, Kisely, S, Hughes, J, Kutcher, S. Prescribing trends of antipsychotics in youth receiving income assistance: results from a retrospective population database study. BMC Psychiatry 2013; 13(198): 1–13.
21Duncan, D, Cooke, L, Symonds, C, Gardner, DM, Pringsheim, T. Quetiapine use in adults in the community: a population-based study in Alberta, Canada. BMJ Open 2016; 6: 1–7.
22Patten, S, Williams, J, Lavorato, D, Fiest, K, Bulloch, A, Wang, J. The prevalence of major depression is not changing. Can J Psychiatry 2015; 60(1): 31–4.
23Schaffer, A, Cairney, J, Cheung, A, Veldhuizen, S, Levitt, A. Community survey of bipolar disorder in Canada: lifetime prevalence and illness characteristics. Can J Psychiatry 2006; 51(1): 9–16.
24McDonald, K, Bulloch, A, Duffy, A, Bresee, L, Williams, J, Lavorato, D, et al. Prevalence of bipolar I and II disorder in Canada. Can J Psychiatry 2015; 60(3): 151–6.
25Herbeck, D, West, J, Ruditis, I, Duffy, F, Fitek, D, Bell, C, et al. Variations in use of second-generation antipsychotic medication by race among adult psychiatric patients. Psychiatr Serv 2004; 55(6): 677–84.
26Opolka, J, Rascati, K, Brown, C, Gibson, P. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. Psychiatr Serv 2004; 55(2): 151–6.
27Connolly, A, Taylor, D. Ethnicity and quality of antipsychotic prescribing among in-patients in south London. Br J Psychiatry 2008; 193(2): 161–2.
29Aronne, L, Segal, K. Weight gain in the treatment of mood disorders. J Clin Psychiatry 2003; 64(suppl 8): 22–9.
30Printz, D, Clark, J, Stricks, L, Malaspina, D. Weight gain in bipolar disorder: causes and treatments. Primary Psychiatry 2003; 10(11): 29–36.
31Haupt, D, Rosenblatt, L, Kim, E, Baker, R, Whitehead, R, Newcomer, J. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 2009; 166(3): 345–53.
32Morrato, E, Druss, B, Hartung, D, Valuck, R, Allen, R, Campagna, E, et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 2010; 67(1): 17–24.